Inteliview
Log inSign up
IPO Tracker
Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc.

USListed
Valuation$302M
Listed DateApril 10, 2026
SectorN/A
Exchange--
RELATED IPOS
L
Lakewood-Amedex Biotherapeutics Inc.Lakewood-Amedex Biotherapeutics Inc.N/A · --
G
General Catalyst Global Resilience Merger Corp.General Catalyst Global Resilience Merger Corp.N/A · $350M
Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc.Hemab Therapeutics Holdings, Inc.N/A · $302M
Avalyn Pharma Inc.
Avalyn Pharma Inc.Avalyn Pharma Inc.N/A · $300M
A
ARC Group Acquisition I Corp.ARC Group Acquisition I Corp.N/A · $105M
SILVER BOW MINING CORP.
SILVER BOW MINING CORP.SILVER BOW MINING CORP.N/A · $65M
FAQ

When is the Hemab Therapeutics Holdings, Inc. IPO expected?

Hemab Therapeutics Holdings, Inc. has already gone public. It listed on April 10, 2026.

What is Hemab Therapeutics Holdings, Inc.'s valuation?

Hemab Therapeutics Holdings, Inc.'s estimated valuation is approximately $302M. It operates in the N/A sector. The final valuation will depend on IPO pricing and market demand.

Can retail investors participate in the Hemab Therapeutics Holdings, Inc. IPO?

U.S. IPOs are typically allocated to institutional investors first. Retail investors can purchase shares on NYSE/NASDAQ after listing. Some brokerages offer IPO access programs for pre-IPO allocation.